VIDEO: Approaching recurrent endometrial cancer

Editor’s note: This is an automatically generated transcript. Please notify iwaters@healio.com if there are concerns regarding accuracy of the transcription.

For patients with recurrent endometrial cancer we actually have had some treatment developments in the last few years. One is that for women who have the serous histology of endometrial cancer we will test them now for HER-2 amplification. This is the same, HER-2 amplification that we talk about with HER-2 positive breast cancer. And we have found that a proportion of women, particularly with the serous histology will have HER-2 amplification and adding a breast cancer drug, Herceptin or trastuzumab to their chemotherapy regimen increases responses.

The other drugs that we're using now for recurrent endometrial cancer are immunotherapy so typically that's pembrolizumab or Keytruda. For women who have, what are known as mismatch repair associated or microsatellite instability high tumors that may be pembrolizumab alone or with combination chemotherapy, or for women who don't have mismatch repair. Combining pembrolizumab with a tyrosine kinase inhibitor called lenvatinib is also been an effective regimen. And so that's become really the go-to second line regimen now for women who have progressed through standard chemotherapy which like most gynecologic cancers is a platinum Taxol based chemotherapy.